v3.26.1
Segment Information (Details)
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Information    
Number of segments | segment 1  
Interest income $ 137,800 $ 187,612
Net loss (17,606,382) (5,537,069)
Single reportable segment    
Segment Information    
Program expenses related to clinical-stage product candidates (15,580,338) (4,217,214)
Program expenses related to preclinical and discovery programs (196,994) (30,600)
Program expenses related to clinical manufacturing candidates (270,830)  
Personnel-related expenses (including stock-based compensation) (1,272,579) (1,397,874)
General and administrative professional and consultant fees (490,577) (444,865)
Other segment items (200,864) (192,128)
Interest income 137,800 187,612
Other non-cash income (expense) items 268,000 558,000
Net loss $ (17,606,382) $ (5,537,069)
Segment Reporting, Other Segment Item, Composition, Description 1 Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses. 2 Other non-cash income (expense) items include the change in fair value of our liability classified warrants.